Background:  IGF-BPs form high affinity complexes with both IGF-I and IGF-II and act to control of the distribution, function and activity of IGFs in various cell tissues and body fluids. There are seven named IGF-BPs. IGFBP7 plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGFBP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. IGFBP7 is expressed in a wide range of normal human tissues and it usually shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.

Description: Rabbit polyclonal to IGFBP7

Immunogen: KLH conjugated synthetic peptide derived from IGFBP7

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 29 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.